Patents Assigned to Pharmascience Inc.
-
Publication number: 20190076366Abstract: The present invention relates to an adhesive-free pharmaceutical composition for the treatment of hepatitis B virus infections, comprising at least one guanine-based antiviral active pharmaceutical ingredient. More specifically, the present invention concerns an oral pharmaceutical composition comprising: adhesive-free granules comprising therapeutically effective amount of entecavir and at least one intra-granular pharmaceutically acceptable excipient; at least one extra-granular pharmaceutical excipient, and, optionally, a moisture barrier coating. A method of manufacturing an adhesive-free pharmaceutical composition is also disclosed.Type: ApplicationFiled: April 3, 2018Publication date: March 14, 2019Applicant: Pharmascience, Inc.Inventors: Mathew Philip, Naresh Talwar
-
Publication number: 20180179210Abstract: The present invention relates to a novel family of kinases inhibitors. Compounds of this class have been found to have inhibitory activity against members of the TEC kinase family, particularly BTK. The present invention is directed to a compound of Formula I or pharmaceutically acceptable salt, solvate, solvate of salt, stereoisomer, tautomer, isotope, prodrug, complex or biologically active metabolite thereof, for use in therapy.Type: ApplicationFiled: May 27, 2016Publication date: June 28, 2018Applicant: Pharmascience Inc.Inventors: Alain Laurent, Yannick Rose, Stephen J. Morris
-
Publication number: 20180117158Abstract: A modified release orally administrable abuse-deterrent pharmaceutical composition comprising: a therapeutically effective amount of an active pharmaceutical ingredient and konjac glucomannan. The active pharmaceutical ingredient can be selected from a number of compounds but is generally aimed to be a compound which is subject to widespread abuse such as opioids.Type: ApplicationFiled: December 27, 2017Publication date: May 3, 2018Applicant: Pharmascience Inc.Inventors: Krishna Hari Bhandari, Naresh Talwar
-
Patent number: 9822120Abstract: The present invention relates to a novel family of protein kinase inhibitors of Formula I: as well as to the processes of preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune or infectious diseases, disorders, or conditions in which protein kinase activity is implicated.Type: GrantFiled: November 20, 2014Date of Patent: November 21, 2017Assignee: Pharmascience Inc.Inventors: Alain Laurent, Yannick Rose
-
Patent number: 9796716Abstract: The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families.Type: GrantFiled: May 28, 2013Date of Patent: October 24, 2017Assignee: PHARMASCIENCE, INC.Inventors: Alain Laurent, Yannick Rose, James B. Jaquith
-
Patent number: 9795608Abstract: The present invention relates to a novel family of inhibitors of protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families.Type: GrantFiled: September 12, 2016Date of Patent: October 24, 2017Assignee: PHARMASCIENCE, INC.Inventors: Alain Laurent, Yannick Rose
-
Publication number: 20170158697Abstract: The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec or Src protein kinase families. The present invention also relates to processes for the preparation of these compounds, to the pharmaceutical composition comprising them, and to their use in the treatment of proliferative, inflammatory, infectious or autoimmune diseases, disorder or condition in which protein kinase activity is implicated.Type: ApplicationFiled: November 26, 2014Publication date: June 8, 2017Applicant: Pharmascience Inc.Inventors: Alain Laurent, Yannick Rose
-
Patent number: 9624239Abstract: The present invention relates to a novel family of inhibitors of protein kinases of Formula (1) wherein X is selected from CH2, O, S(0)n, or NR6; and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src, Btk and Lck protein kinase families.Type: GrantFiled: April 3, 2012Date of Patent: April 18, 2017Assignee: Pharmascience Inc.Inventors: Alain Laurent, Yannick Rose, Stephen Morris, James Jaquith
-
Publication number: 20170014340Abstract: Orally disintegrating medicaments comprising Nabilone allow for improved treatment of nausea arising from chemo therapy for cancer. The medicaments comprise appropriate excipients such that the medicament disintegrates in the mouth in 30 seconds or less, while exhibiting sufficient stability for storage. In a preferred embodiment, the medicament is in the form of a tablet formed from granules. The granules consist of an intra-granular fraction comprising nabilone, mannitol, and polyvinyl pyrrolidone and an extra-granular fraction comprising mannitol, calcium silicate, crospovidone, and magnesium stearate. Processes for manufacturfing such medicaments are also disclosed.Type: ApplicationFiled: March 4, 2015Publication date: January 19, 2017Applicant: Pharmascience Inc.Inventors: Ousmane Diallo, Mathew Philip, Naresh Talwar
-
Publication number: 20160375027Abstract: The present invention relates to a novel family of inhibitors of protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families.Type: ApplicationFiled: September 12, 2016Publication date: December 29, 2016Applicant: PHARMASCIENCE, INC.Inventors: Alain LAURENT, Yannick ROSE
-
Publication number: 20160289236Abstract: The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec or Src protein kinase families. The present invention also relates to the processes of preparation of these compounds, their intermediates, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune, or infectious diseases, disorders, or conditions in which protein kinase activity is implicated.Type: ApplicationFiled: November 19, 2014Publication date: October 6, 2016Applicant: Pharmascience Inc.Inventors: Alain Laurent, Yannick Rose
-
Publication number: 20160280711Abstract: The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the Tec or Src protein kinase families. The present invention also relates to the processes of preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune or infectious diseases, disorders, or conditions in which protein kinase activity is implicated.Type: ApplicationFiled: November 20, 2014Publication date: September 29, 2016Applicant: Pharmascience Inc.Inventors: Alain Laurent, Yannick Rose
-
Patent number: 9447102Abstract: The present invention relates to a novel family of inhibitors of protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families.Type: GrantFiled: July 3, 2013Date of Patent: September 20, 2016Assignee: PHARMASCIENCE, INC.Inventors: Alain Laurent, Yannick Rose
-
Patent number: 9365614Abstract: A compound of Formula I or a salt thereof, methods for the preparation thereof, and related methods and compositions.Type: GrantFiled: May 23, 2014Date of Patent: June 14, 2016Assignee: Pharmascience Inc.Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
-
Publication number: 20160106680Abstract: The present invention relates to an immediate release orally administrable abuse-deterrent pharmaceutical formulation comprising: at least one pharmaceutically active ingredient susceptible to abuse; at least one gelling polymeric compound selected from the group consisting of: polysaccharides, sugars, sugar derived alcohols, starches, starch derivatives, cellulose derivatives, Carrageenan, pectin, sodium alginate, gellan gum, xanthan gum, poloxamer, Carbopol®, PolyOx®, povidone, hydroxypropyl methylcellulose (HPMC), hypermellose, and combinations thereof; at least one disintegrant and optionally at least one surfactant, wherein said formulation exhibit properties related to deterring the abuse, via injection or nasal inhalation when being tampered and exposed to aqueous, alcoholic, acidic and basic media.Type: ApplicationFiled: May 30, 2014Publication date: April 21, 2016Applicant: Pharmascience Inc.Inventors: Krishna Hari Bhandari, Naresh Talwar
-
Patent number: 9284318Abstract: The present invention relates to novel kinase inhibitors. Compounds of this class have been found to be effective inhibitors of protein kinases, including members of PDGFR and VEGFR families.Type: GrantFiled: April 3, 2012Date of Patent: March 15, 2016Assignee: Pharmascience, Inc.Inventors: Alain Laurent, Yannick Rose, Stephen Morris, James Jaquith
-
Patent number: 9284350Abstract: A compound of Formula 1: (I) or salt thereof, as well as methods of making compounds of Formula 1, methods of using compounds of Formula 1 to treat proliferative disorders such as cancer, and related compounds, composition, and methods.Type: GrantFiled: February 11, 2011Date of Patent: March 15, 2016Assignee: Pharmascience Inc.Inventors: Alain Laurent, Melanie Proulx, Yannick Rose, Irina Denissova, Kenza Dairi, Scott Jarvis, James B. Jaquith
-
Publication number: 20150250886Abstract: A modified release orally administrable abuse-deterrent pharmaceutical composition comprising: a therapeutically effective amount of an active pharmaceutical ingredient and konjac glucomannan. The active pharmaceutical ingredient can be selected from a number of compounds but is generally aimed to be a compound which is subject to widespread abuse such as opioids.Type: ApplicationFiled: September 30, 2013Publication date: September 10, 2015Applicant: PHARMASCIENCE INC.Inventors: Krishna Hari Bhandari, Naresh Talwar
-
Publication number: 20150191473Abstract: The present invention relates to a novel family of inhibitors of protein kinases. In particular, the present invention relates to inhibitors of the members of the Tec and Src protein kinase families.Type: ApplicationFiled: May 28, 2013Publication date: July 9, 2015Applicant: Pharmascience, Inc.Inventors: Alain Laurent, Yannick Rose, James B. Jaquith
-
Publication number: 20140336134Abstract: A compound of Formula I or a salt thereof, methods for the preparation thereof, and related methods and compositions.Type: ApplicationFiled: May 23, 2014Publication date: November 13, 2014Applicant: Pharmascience Inc.Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent